Abstract
Phenobarbital is an effective and safe anticonvulsant drug introduced in clinical use in 1904. Its mechanism of action is the synaptic inhibition through an action on GABAA. The loading dose of phenobarbital is 20 mg/kg intravenously and the maintenance dose is 3 to 4 mg/kg by mouth. The serum concentration of phenobarbital is up to 40 g/ml. Nonresponders should receive additional doses of 5 to 10 mg/kg until seizures stop. Infants with refractory seizures may have a serum concentration of phenobarbital of 100 g/ml. Phenobarbital is metabolized in the liver by CYP2C9 with minor metabolism by CYP2C19 and CYP2E1. A quarter of the dose of phenobarbital is excreted unchanged in the urine. In adults, the half-life of phenobarbital is 100 hours and in term and preterm infants is 103 and 141 hours, respectively. The half-life of phenobarbital decreases 4.6 hours per day and it is 67 hours in infants 4 week old.
Keywords: Dosing, metabolism, neonate, pharmacokinetics, phenobarbital, serum-levels.
Current Pediatric Reviews
Title:Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics
Volume: 12 Issue: 1
Author(s): Gian M. Pacifici
Affiliation:
Keywords: Dosing, metabolism, neonate, pharmacokinetics, phenobarbital, serum-levels.
Abstract: Phenobarbital is an effective and safe anticonvulsant drug introduced in clinical use in 1904. Its mechanism of action is the synaptic inhibition through an action on GABAA. The loading dose of phenobarbital is 20 mg/kg intravenously and the maintenance dose is 3 to 4 mg/kg by mouth. The serum concentration of phenobarbital is up to 40 g/ml. Nonresponders should receive additional doses of 5 to 10 mg/kg until seizures stop. Infants with refractory seizures may have a serum concentration of phenobarbital of 100 g/ml. Phenobarbital is metabolized in the liver by CYP2C9 with minor metabolism by CYP2C19 and CYP2E1. A quarter of the dose of phenobarbital is excreted unchanged in the urine. In adults, the half-life of phenobarbital is 100 hours and in term and preterm infants is 103 and 141 hours, respectively. The half-life of phenobarbital decreases 4.6 hours per day and it is 67 hours in infants 4 week old.
Export Options
About this article
Cite this article as:
Pacifici M. Gian, Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics, Current Pediatric Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573397111666151026223914
DOI https://dx.doi.org/10.2174/1573397111666151026223914 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews GABA-A Receptor Complex and Memory Processes
Current Topics in Medicinal Chemistry Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Voltage-Gated Sodium Channels in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Oxidative Stress-Induced Caspases are Regulated in Human Myeloid HL-60 Cells by Calcium Signal
Current Signal Transduction Therapy Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands
Current Medicinal Chemistry - Central Nervous System Agents Histamine H3 Receptor Ligands in the Group of (Homo)piperazine Derivatives
Current Medicinal Chemistry Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer’s Disease
Current Pharmaceutical Design Postpartum Psychiatric Disorders: What Do We Know And Where Do We Go?
Current Psychiatry Reviews Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors
Current Pharmaceutical Design Antiepileptic Treatment Strategy in Vascular Malformations
Current Pharmaceutical Design Drugs of Abuse and their Detection Methodologies: Contribution of Chemical Sensor
Current Organic Chemistry Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders
Current Molecular Medicine A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Natural AChE Inhibitors from Plants and their Contribution to Alzheimer’s Disease Therapy
Current Neuropharmacology Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Synthesis, Anticonvulsant and Neurotoxicity Evaluation of Some Newer N-(2-benzoylbenzofuran-3-yl)-3-(substituted)-propanamide Analogs
Central Nervous System Agents in Medicinal Chemistry Triheptanoin Supplementation to Ketogenic Diet Curbs Cognitive Impairment in APP/PS1 Mice Used as a Model of Familial Alzheimer’s Disease
Current Alzheimer Research Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior
Current Genomics